Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 15, 2019 - Issue 6
Submit an article Journal homepage
861
Views
12
CrossRef citations to date
0
Altmetric
Original Research

Monoclonal antibodies in severe asthma: is it worth it?

Luigino CalzettaUnit of Respiratory Medicine, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome, Italy;Department of Health Sciences, University of Catanzaro “Magna Græcia”, Catanzaro, ItalyCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-0456-069XView further author information
ORCID Icon,
Maria Gabriella MateraUnit of Pharmacology, Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, ItalyView further author information
&
Paola RoglianiUnit of Respiratory Medicine, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome, ItalyView further author information
Pages 517-520 | Received 11 Feb 2019, Accepted 17 May 2019, Published online: 23 May 2019

References

  • Brussino L, Solidoro P, Rolla G. Is it severe asthma or asthma with severe comorbidities? J Asthma Allergy. 2017;10:303-305.
  • Chastek B, Korrer S, Nagar SP, et al. Economic burden of illness among patients with severe asthma in a managed care setting. J Manag Care Spec Pharm. 2016;22:848–861.
  • Cazzola M, Segreti A, Calzetta L, et al. Comorbidities of asthma: current knowledge and future research needs. Curr Opin Pulm Med. 2013;19:36–41.
  • Wechsler ME. Getting control of uncontrolled asthma. Am J Med. 2014;127:1049–1059.
  • Grainge CL, Maltby S, Gibson PG, et al. Targeted therapeutics for severe refractory asthma: monoclonal antibodies. Expert Rev Clin Pharmacol. 2016;9:927–941.
  • Bagnasco D, Heffler E, Testino E, et al. Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment. Expert Opin Drug Metab Toxicol. 2019;15:113–120.
  • Cazzola M, Rogliani P, Calzetta L, et al. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018;13:52.
  • Calzetta L, Cazzola M, Matera MG, et al. Adding a LAMA to ICS/LABA therapy: a meta-analysis of triple combination therapy in COPD. Chest. 2019;155:758–770.
  • Cazzola M, Rogliani P, Calzetta L, et al. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. Copd. 2017;14:552–563.
  • Wallace BC, Dahabreh IJ, Trikalinos TA, et al. Closing the gap between methodologists and end-users: R as a computational back-end. J Stat Softw. 2012;49:1–15.
  • van Valkenhoef G, Lu G, de Brock B, et al. Automating network meta-analysis. Res Synth Methods. 2012;3:285–299.
  • Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence–imprecision. . J Clin Epidemiol. 2011;64:1283–1293.
  • Jones PW, Beeh KM, Chapman KR, et al. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med. 2014;189:250–255.
  • Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–1197.
  • Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448–2458.
  • Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475–2485.
  • Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5:390–400.
  • Pelaia C, Calabrese C, Terracciano R, et al. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness. Ther Adv Respir Dis. 2018;12:1753466618810192.
  • Morjaria JB, Emma R, Fuochi V, et al. An evaluation of mepolizumab for the treatment of severe asthma. Expert Opin Biol Ther. 2019.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.